Xponance Inc. Invests $261,000 in Guardant Health, Inc. (NASDAQ:GH)

Xponance Inc. acquired a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,534 shares of the company’s stock, valued at approximately $261,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Intech Investment Management LLC bought a new position in Guardant Health in the third quarter valued at about $754,000. Cerity Partners LLC lifted its stake in shares of Guardant Health by 54.6% in the 3rd quarter. Cerity Partners LLC now owns 195,008 shares of the company’s stock worth $4,473,000 after purchasing an additional 68,883 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Guardant Health by 6.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,986 shares of the company’s stock worth $665,000 after purchasing an additional 1,844 shares in the last quarter. Verition Fund Management LLC raised its holdings in Guardant Health by 220.6% in the 3rd quarter. Verition Fund Management LLC now owns 37,641 shares of the company’s stock worth $863,000 after purchasing an additional 25,900 shares during the period. Finally, Eventide Asset Management LLC lifted its position in Guardant Health by 2.0% during the third quarter. Eventide Asset Management LLC now owns 3,837,300 shares of the company’s stock valued at $88,028,000 after purchasing an additional 76,762 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Trading Down 4.5 %

NASDAQ:GH opened at $43.14 on Friday. The company has a market capitalization of $5.32 billion, a P/E ratio of -12.12 and a beta of 1.50. The business’s 50-day moving average is $44.66 and its 200 day moving average is $34.24. Guardant Health, Inc. has a 12 month low of $15.81 and a 12 month high of $50.89.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. On average, research analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GH has been the subject of a number of analyst reports. Morgan Stanley upped their price target on Guardant Health from $42.00 to $52.00 and gave the stock an “overweight” rating in a research report on Thursday, March 6th. Stephens reissued an “overweight” rating and issued a $55.00 target price on shares of Guardant Health in a report on Wednesday. The Goldman Sachs Group raised their target price on shares of Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Scotiabank upped their price target on shares of Guardant Health from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Monday, February 24th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Twenty analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $48.95.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.